New Imaging Agent Able to Capture Prostate Cancer Metastasis in Bone and Soft Tissue

New Imaging Agent Able to Capture Prostate Cancer Metastasis in Bone and Soft Tissue
A new imaging agent  has been found to be safe, fast, and efficient in visualizing metastatic prostate cancer, even in regions where the visualization is often challenging, such as bone and soft tissues. The study, the results of a Phase 1/2a clinical trial (NCT01923727) in prostate cancer patients, was titled, “First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake,” were published in the Journal of Nuclear Medicine. One of the dangers of cancer — including prostate cancer — is the ability of cancer cells to turn metastatic and spread elsewhere in the body. To visualize cancer and possible metastasis, cancer cells need to be labeled in a way that allows them to be distinguished from normal cells.  In general, florescent dyes are used for this purpose, but current visualization methods often have limitations, such as slow visualization time, toxicity, and low visualization in areas like bones and tissues. A new imaging agent, a radiotracer called 89Zr-Df-IAB2M, was tested to see how well it aided scanning methods (positron emission tomography [PET]  and computed tomography [CT]) in determining metastasis. A total of 18 patients were injected with 89Zr-IAB2M  at various doses: 6 were given 10 mg, another 6 at 20 mg, and the final 6 patients at 50 mg. They were then
Subscribe or to access all post and page content.